Jade Biosciences, Inc.

NASDAQ: JBIO · Healthcare · Biotechnology

PublicHQ Waltham, MA · MiddlesexCIK 0001798749Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 60DQ —GM —SS 45

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$127.4M

Employees

as of 2026-08-11

Market cap

$709.0M

as of 2026-08-11

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$127.4M-$127.4M2025

Operating income-$113.5M-$113.5M2025

Total assets$349.8M$349.8M2025

Liabilities$17.3M$17.3M2025

Equity$332.5M$332.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Jade Biosciences, Inc.’s financial profile?

Jade Biosciences, Inc. earned -$127.4M in FY2025 net income.

Peers · Healthcare

SpyGlass Pharma, Inc. Common Stock——BridgeBio Oncology Therapeutics Inc.——Cybin Inc. Common Stock——Tectonic Therapeutic, Inc.——Adlai Nortye Ltd.——GMR Solutions Inc.——

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Symbotic Inc.$2.2B49D

Key facts

CEOTom Frohlich

SectorHealthcare

IndustryBiotechnology

HeadquartersWaltham, MA

ExchangeNASDAQ: JBIO

Employees55

IPO date2025-04-29

Latest filings

10-Q2026-08-10 8-K2026-08-10 8-K2026-07-01 8-K2026-06-26 8-K2026-06-11 8-K2026-06-04 8-K2026-06-01 8-K2026-05-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.